Theravance Biopharma, Inc. (TBPH)
17.04
0.00 (0.00%)
USD |
NASDAQ |
Sep 01, 16:00
17.04
0.00 (0.00%)
After-Hours: 18:51
Theravance Biopharma Cash from Operations (TTM) : 53.74M for June 30, 2026
Cash from Operations (TTM) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Cash from Operations (TTM) Data
| Date | Value |
|---|---|
| June 30, 2026 | 53.74M |
| March 31, 2026 | 268.78M |
| December 31, 2025 | 238.54M |
| September 30, 2025 | 243.70M |
| June 30, 2025 | 245.02M |
| March 31, 2025 | 32.53M |
| December 31, 2024 | -11.54M |
| September 30, 2024 | -11.49M |
| June 30, 2024 | -8.777M |
| March 31, 2024 | -16.80M |
| December 31, 2023 | -27.00M |
| September 30, 2023 | -150.20M |
| June 30, 2023 | -169.85M |
| March 31, 2023 | -172.14M |
| December 31, 2022 | -186.99M |
| September 30, 2022 | -105.37M |
| June 30, 2022 | -128.68M |
| March 31, 2022 | -164.06M |
| December 31, 2021 | -207.86M |
| September 30, 2021 | -230.35M |
| June 30, 2021 | -261.93M |
| March 31, 2021 | -265.17M |
| December 31, 2020 | -250.40M |
| September 30, 2020 | -249.83M |
| June 30, 2020 | -217.42M |
| Date | Value |
|---|---|
| March 31, 2020 | -212.10M |
| December 31, 2019 | -238.20M |
| September 30, 2019 | -226.02M |
| June 30, 2019 | -230.38M |
| March 31, 2019 | -243.88M |
| December 31, 2018 | -112.87M |
| September 30, 2018 | -104.89M |
| June 30, 2018 | -118.21M |
| March 31, 2018 | -101.20M |
| December 31, 2017 | -201.05M |
| September 30, 2017 | -184.96M |
| June 30, 2017 | -135.10M |
| March 31, 2017 | -122.71M |
| December 31, 2016 | -98.99M |
| September 30, 2016 | -104.62M |
| June 30, 2016 | -124.17M |
| March 31, 2016 | -138.65M |
| December 31, 2015 | -168.86M |
| September 30, 2015 | -177.65M |
| June 30, 2015 | -182.04M |
| March 31, 2015 | -186.87M |
| December 31, 2014 | -175.16M |
| September 30, 2014 | -167.80M |
| June 30, 2014 | -164.36M |
| March 31, 2014 | -137.27M |
Cash From Operations Definition
Represents the net cash flow from the company's business operations.
Cash from Operations (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Operations (TTM) Benchmarks
| Zymeworks, Inc. | -119.20M |
| Viatris, Inc. | 2.331B |
| Ocular Therapeutix, Inc. | -238.24M |
| ANI Pharmaceuticals, Inc. | 189.47M |
| Corcept Therapeutics, Inc. | 109.70M |